![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ajovy (fremanezumab) is a FDA approved, humanized monoclonal antibody which selectively binds the calcitonin gene-related peptide, it is indicated for preventive treatment of migraine in adults.
Lead Product(s): Fremanezumab
Therapeutic Area: Neurology Product Name: Ajovy
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2024
Details:
Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Victoza-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Details:
Lotus will gain access to Teva’s ophthalmic and respiratory portfolio, including NATEAR (hydroxypropyl methylcellulose) used as artificial tears to prevent conjunctival and corneal damage.
Lead Product(s): Hypromellose
Therapeutic Area: Ophthalmology Product Name: Natear
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lotus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 06, 2024
Details:
FDA has approved Teva's AUSTEDO XR (deutetrabenazine,vmat2 inhibitor) extended-release tablets as a once-daily treatment option for adults with tardive dyskinesia and Huntington’s disease chorea.
Lead Product(s): Deutetrabenazine
Therapeutic Area: Genetic Disease Product Name: Austedo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2024
Details:
TEV-‘749 is being developed as a once-monthly subcutaneous long-acting injection of olanzapine with the use of SteadyTeq™ technology, a copolymer technology for the treatment of adults with schizophrenia.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Product Name: TEV-‘749
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MedinCell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Details:
Selarsdi (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: Selarsdi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Alvotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Ajovy is a FDA approved, humanized monoclonal antibody (mAb) which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in adult Chinese patients.
Lead Product(s): Fremanezumab
Therapeutic Area: Neurology Product Name: Ajovy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
mAbxience will leverage its expertise in biosimilar development to develop and produce the biosimilar product currently in development for the treatment of multiple oncology indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Mabxience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 04, 2024
Details:
The collaboration aims to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for patients with asthma.
Lead Product(s): Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TEV-56248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Launch Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2024
Details:
The net proceeds will be used to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-56248), albuterol/fluticasone combination, currently in Phase 3 clinical trials for patients with asthma.
Lead Product(s): Fluticasone Propionate,Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TEV-56248
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abingworth
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 01, 2024